Randomized phase 2 trial comparing JNJ‐9375, a thrombin‐directed antibody, with apixaban for prevention of venous thrombosis

BackgroundJNJ‐9375 is an antibody against exosite 1 on thrombin, inhibits substrate binding but not catalytic activity.ObjectiveTo examine the possibility that JNJ‐9375 attenuates thrombosis without affecting hemostasis, we compared the efficacy and safety of JNJ‐9375 and apixaban.MethodsIn this double‐blind, double‐dummy phase 2 trial, 308 patients undergoing knee arthroplasty were randomized to receive either a single postoperative intravenous...